191 related articles for article (PubMed ID: 31444332)
1. Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.
Schipper K; Seinstra D; Paulien Drenth A; van der Burg E; Ramovs V; Sonnenberg A; van Rheenen J; Nethe M; Jonkers J
Nat Commun; 2019 Aug; 10(1):3800. PubMed ID: 31444332
[TBL] [Abstract][Full Text] [Related]
2. Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.
Schipper K; Drenth AP; van der Burg E; Cornelissen S; Klarenbeek S; Nethe M; Jonkers J
Cancer Res; 2020 Apr; 80(7):1486-1497. PubMed ID: 32060147
[TBL] [Abstract][Full Text] [Related]
3. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.
de Groot JS; Ratze MA; van Amersfoort M; Eisemann T; Vlug EJ; Niklaas MT; Chin SF; Caldas C; van Diest PJ; Jonkers J; de Rooij J; Derksen PW
J Pathol; 2018 Aug; 245(4):456-467. PubMed ID: 29774524
[TBL] [Abstract][Full Text] [Related]
4. PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
Boelens MC; Nethe M; Klarenbeek S; de Ruiter JR; Schut E; Bonzanni N; Zeeman AL; Wientjens E; van der Burg E; Wessels L; van Amerongen R; Jonkers J
Cell Rep; 2016 Aug; 16(8):2087-2101. PubMed ID: 27524621
[TBL] [Abstract][Full Text] [Related]
5. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.
Derksen PW; Braumuller TM; van der Burg E; Hornsveld M; Mesman E; Wesseling J; Krimpenfort P; Jonkers J
Dis Model Mech; 2011 May; 4(3):347-58. PubMed ID: 21282721
[TBL] [Abstract][Full Text] [Related]
6. p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.
Tenhagen M; Klarenbeek S; Braumuller TM; Hofmann I; van der Groep P; Ter Hoeve N; van der Wall E; Jonkers J; Derksen PW
J Mammary Gland Biol Neoplasia; 2016 Dec; 21(3-4):81-88. PubMed ID: 27411687
[TBL] [Abstract][Full Text] [Related]
7. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
Derksen PW; Liu X; Saridin F; van der Gulden H; Zevenhoven J; Evers B; van Beijnum JR; Griffioen AW; Vink J; Krimpenfort P; Peterse JL; Cardiff RD; Berns A; Jonkers J
Cancer Cell; 2006 Nov; 10(5):437-49. PubMed ID: 17097565
[TBL] [Abstract][Full Text] [Related]
8. Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
Corsino PE; Davis BJ; Nørgaard PH; Parker NN; Law M; Dunn W; Law BK
Neoplasia; 2008 Nov; 10(11):1240-52. PubMed ID: 18953433
[TBL] [Abstract][Full Text] [Related]
9. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.
Annunziato S; Kas SM; Nethe M; Yücel H; Del Bravo J; Pritchard C; Bin Ali R; van Gerwen B; Siteur B; Drenth AP; Schut E; van de Ven M; Boelens MC; Klarenbeek S; Huijbers IJ; van Miltenburg MH; Jonkers J
Genes Dev; 2016 Jun; 30(12):1470-80. PubMed ID: 27340177
[TBL] [Abstract][Full Text] [Related]
10. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
Yang J; Mani SA; Donaher JL; Ramaswamy S; Itzykson RA; Come C; Savagner P; Gitelman I; Richardson A; Weinberg RA
Cell; 2004 Jun; 117(7):927-39. PubMed ID: 15210113
[TBL] [Abstract][Full Text] [Related]
11. LGR6-dependent conditional inactivation of E-cadherin and p53 leads to invasive skin and mammary carcinomas in mice.
Ter Steege EJ; Sijnesael T; Enserink L; Klarenbeek S; Haakma WE; Bakker ERM; Derksen PWB
Neoplasia; 2023 Jan; 35():100844. PubMed ID: 36371908
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
13. TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.
Cornelissen LM; Drenth AP; van der Burg E; de Bruijn R; Pritchard CEJ; Huijbers IJ; Zwart W; Jonkers J
Genes Dev; 2020 Feb; 34(3-4):179-193. PubMed ID: 31879358
[TBL] [Abstract][Full Text] [Related]
14. Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.
Elangovan A; Hooda J; Savariau L; Puthanmadhomnarayanan S; Yates ME; Chen J; Brown DD; McAuliffe PF; Oesterreich S; Atkinson JM; Lee AV
Mol Cancer Res; 2022 Sep; 20(9):1405-1419. PubMed ID: 35665642
[TBL] [Abstract][Full Text] [Related]
15. Expression of the cytoplasmic domain of E-cadherin induces precocious mammary epithelial alveolar formation and affects cell polarity and cell-matrix integrity.
Delmas V; Pla P; Feracci H; Thiery JP; Kemler R; Larue L
Dev Biol; 1999 Dec; 216(2):491-506. PubMed ID: 10642788
[TBL] [Abstract][Full Text] [Related]
16. mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma.
Alvarez JV; Perez D; Chodosh LA
Cancer Cell; 2006 Nov; 10(5):347-9. PubMed ID: 17097555
[TBL] [Abstract][Full Text] [Related]
17. Special considerations in mouse models of breast cancer.
Borowsky A
Breast Dis; 2007; 28():29-38. PubMed ID: 18057541
[No Abstract] [Full Text] [Related]
18. Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation.
Kotb AM; Hierholzer A; Kemler R
Breast Cancer Res; 2011 Oct; 13(5):R104. PubMed ID: 22030022
[TBL] [Abstract][Full Text] [Related]
19. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
[TBL] [Abstract][Full Text] [Related]
20. Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
Rätze MAK; Koorman T; Sijnesael T; Bassey-Archibong B; van de Ven R; Enserink L; Visser D; Jaksani S; Viciano I; Bakker ERM; Richard F; Tutt A; O'Leary L; Fitzpatrick A; Roca-Cusachs P; van Diest PJ; Desmedt C; Daniel JM; Isacke CM; Derksen PWB
Oncogene; 2022 May; 41(21):2932-2944. PubMed ID: 35437308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
